Research Programme Sample Clauses

Research Programme. EVOTEC and BOEHRINGER wish to enter into a joint research collaboration in order to identify small chemical entity therapeutics which act as GPCR modulators. Their first and initial priority is GPCR targets for CNS diseases but the collaboration may include additional GPCR target opportunities for other diseases, including but not limited to ****, ****, ****, **** and **** areas. The Parties acknowledge that EVOTEC OAI AG has entered into an exclusive collaboration in the area of ****. The GPCR Targets in the respective indication area will be determined by the appropriate committee in accordance with the provisions of Section 3. The Research Programme is also intended to generate proprietary know how with respect to GPCRs to be incorporated into ****. Targets shall be selected within the following classes: **** **** **** The Research Plan will be set up in accordance with Section 3. * Portions of this document marked with **** have been omitted pursuant to a request for confidential treatment submitted with the SEC.
Sample 1
AutoNDA by SimpleDocs
Research Programme. 2.01 CAT and HGS will conduct collaborative research and development with respect to Target 1 and to each subsequent Target designated pursuant to Clause 20 ("the Research Programme"). 2.02 Each Party will mutually disclose all information concerning Target Antibodies and the Target, which is necessary for each to perform their duties under the Research Programme, including information relating to selection, derivation and assays relating to Target Antibodies and the Target as developed under the Research Programme. HGS shall specify the animal model for demonstration of In-Vivo Proof of Concept in respect of Target 1 not later than [***] after the Effective Date. HGS shall specify the animal model for demonstration of In-Vivo Proof of Concept in respect of Targets 2 and 3 by a date to be agreed by the JMC. 2.03 The Parties will establish a Joint Management Committee ("JMC") pursuant to Article 4 and each Party shall fund its own costs of the Research Programme. The Parties will collaborate and if required by the JMC employees will work with employees of the other Party at that Party's premises. 2.04 The purpose of the Research Programme will be to generate diverse panels of Target Antibodies and to use them to explore in vivo and in vitro biological characteristics and disease association of the Target and to generate a lead Target Antibody for pre-clinical and subsequent development of a Clinical Development Antibody. 2.05 The parties shall use reasonable efforts to fulfill their obligations as set out in Exhibit A to develop a Clinical Development Antibody and in respect of Targets 2 and 3 to meet any applicable Technical Performance Criteria in respect of Targets 2 and 3.
Sample 1
Research Programme. 2.1 Following signature of this AGREEMENT and payment to ARROW by TRIANGLE of the sum set out in Section 6.1 hereof, 2.1.1 ARROW shall initiate the screening campaign as set out in the RESEARCH PROGRAMME. ARROW shall use its best efforts to identify one or more lead candidates for evaluation by TRIANGLE but the final selection and prioritisation of SELECTED COMPOUNDS to be screened in the HCV Replicase Assay will be made by the JOINT STEERING COMMITTEE. For purposes of this AGREEMENT, "best efforts" shall mean that ARROW shall use efforts which are consistent with those used by it in its other research projects deemed to have comparable commercial potential. 2.1.2 ARROW and TRIANGLE shall set up a JOINT STEERING COMMITTEE with representatives from both companies, the function and terms of reference of which are set out in Article 8 hereof. 2.1.3 ARROW and TRIANGLE shall collaborate through the auspices of the JOINT STEERING COMMITTEE to agree protocols for the pre-clinical (ADME studies) and the clinical studies in good time prior to their intended commencement dates. 2.2 For the duration of the RESEARCH PROGRAMME as defined in Section 2.3 hereof, TRIANGLE shall have the right to submit up to *** compounds to be screened by ARROW at *** cost to TRIANGLE and the prioritisation of the TRIANGLE-SOURCED COMPOUNDS to be screened in the HCV Replicase Assay will ---------- *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. be made by the JOINT STEERING COMMITTEE. 2.3 The RESEARCH PROGRAMME shall continue for an *** from EFFECTIVE DATE hereof extendable for up to a *** at TRIANGLE'S request subject to agreement by both parties of the terms of such extension including the costs therefor. 2.4 A SELECTED COMPOUND, will be removed by ARROW from the library of ARROW-SOURCED COMPOUNDS for all further screening purposes immediately following selection thereof. ARROW agrees not to use the library of ARROW-SOURCED COMPOUNDS in any screening programme for any HCV activity for the duration of the RESEARCH PROGRAMME. 2.5 Upon TRIANGLE's request, ARROW will promptly provide TRIANGLE with such information in ARROW's possession as may be reasonably useful to assist the JOINT STEERING COMMITTEE in its efforts to make a selection from the ARROW-SOURCED COMPOUNDS.
Sample 1
Research Programme. The scientific programme builds the foundation of a long-term European research & training network in the field of optimal control theory, with emphasis
Sample 1
Research Programme. The IT4BI-DC research programme has been established to tackle six fundamental BI challenges for the years to come: Modeling and Semantics, Information Discovery, Information Integration, Big Data Analytics, Large-Scale Processing, and Collaboration and Privacy. A set of Joint Doctoral Topics will be offered from a European-wide coordinated list, each topic fitting within at least one of the six BI challenges. The topics will be competitively selected for their high scientific quality and for their appropriateness with the jointly designed research agenda. Each topic is jointly co-supervised by two universities of the Consortium. The associated partners will provide input for topic definition.
Sample 1
Research Programme 
Sample 1Sample 2Sample 3See All (4)

Related to Research Programme

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Project The findings of any research project, which would change the provisions of this Agreement will not be implemented until such changes are negotiated and agreed to by the parties.

  • Development Program RWJPRI shall be [**] and have [**] in consultation with the JDAC, to select LICENSED COMPOUNDS which shall then be designated PRODUCTS for further DEVELOPMENT by RWJPRI and marketing by ORTHO and its AFFILIATES. RWJPRI shall provide KOSAN with written notice of its decision to select a LICENSED COMPOUND for DEVELOPMENT. Once a PRODUCT has been selected for further DEVELOPMENT, RWJPRI, with the advice of the JDAC, shall have the [**] right to develop the PRODUCT through STAGES O, I, II and III and shall have the [**] right to prepare and file, and shall be the owner of, all applications for MARKETING AUTHORIZATION throughout the world. During such DEVELOPMENT efforts, KOSAN will assist RWJPRI as may be mutually agreed, at RWJPRI's expense, in chemical development, formulation development, production of labeled material and production of sufficient quantities of material for STAGE O and initial STAGE I studies. RWJPRI shall exercise diligent efforts, commensurate with the efforts it would normally exercise for products with similar potential sales volume and consistent with its overall business strategy, in developing such PRODUCT in accordance with the DEVELOPMENT PLAN established by RWJPRI. In the course of such efforts RWJPRI shall, either directly or through an AFFILIATE or SUBLICENSEE to which the license shall have been extended, take appropriate steps including the following: (i) in consultation with the JDAC, select certain LICENSED COMPOUNDS for STAGE O DEVELOPMENT; and (ii) establish and maintain a program reasonably designed, funded and resourced to obtain information adequate to enable the preparation and filing with an appropriate and properly empowered national regulatory authority all necessary documentation, data and [**] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. other evidence required for IND non-rejection to commence and conduct human clinical trials of such PRODUCT. (iii) proceed following IND non-rejection to commence PHASE I, II, and III clinical trials, associated studies and such other work which RWJPRI reasonably deems to be required for subsequent inclusion in filings for MARKETING AUTHORIZATION; (iv) after such submissions are filed prosecute such submissions and file all reasonably necessary, reports and respond to all reasonable requests from the pertinent regulatory, authorities for information, data, samples, tests and the like.

  • Collaboration 31.1 If the Buyer has specified in the Order Form that it requires the Supplier to enter into a Collaboration Agreement, the Supplier must give the Buyer an executed Collaboration Agreement before the Start date. 31.2 In addition to any obligations under the Collaboration Agreement, the Supplier must: 31.2.1 work proactively and in good faith with each of the Buyer’s contractors 31.2.2 co-operate and share information with the Buyer’s contractors to enable the efficient operation of the Buyer’s ICT services and G-Cloud Services

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Term The term “

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!